In addition, the company has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,478,873 common shares from the company on the same terms and conditions.
Bellus Health's common shares are now dual-listed on the NASDAQ Global Market and the Toronto Stock Exchange under the trading symbol "BLU."
The company intends to use the net proceeds of the offering primarily to fund research and development activities, general and administrative expenses, working capital needs and other general corporate purposes, as set out in the Supplement.
Jefferies, Cowen and Guggenheim Securities acted as joint book-running managers, Baird acted as lead manager, and Bloom Burton Securities acted as co-manager for the offering.
Insiders of the company, chairman of Board Dr. Francesco Bellini, director Franklin M. Berger and Orbimed Advisors LLC, of which director Chau Q. Khuong is a partner, purchased an aggregate of 855,845 common shares under the offering or 8.68% of the shares issued under the offering.
Being insiders of the company, subscriptions for common shares by Dr. Bellini, Berger and Orbimed are related party transactions within the meaning of applicable Canadian securities laws.
The subscriptions by Dr. Bellini, Berger and Orbimed are exempt from the formal valuation and minority approval requirements applicable to related party transactions on the basis that the value of the transactions insofar as they involve related parties is less than 25% of the company's market capitalisation.
The board of directors of the company has approved the offering, and each of Dr. Bellini, Berger and Khuong declared their respective interest and abstained from voting thereon.
Bellus Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.
The company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment